US › Healthcare

ANI Pharmaceuticals Inc (ANIP)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$79.20-1.07%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$237.5M
Revenue YoY
+20.5%
Net profit
$29.5M
Profit YoY
+88.1%
EPS
$1.68
EPS estimate
$0.96
Net margin
12.4%

EPS came in at 1.68 against a street estimate of 0.96 — a beat of 75.0%.

Key statistics

Market cap
$1.82B
P/E
20.5
Forward P/E
8.9
P/B
3.20
Book value
$26.34
EPS (TTM)
$3.91
52-week high
$99.50
52-week low
$64.99
50-day MA
$81.11
200-day MA
$81.24
Beta
0.46

Analyst view

Analysts rate ANI Pharmaceuticals Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $110.00.

Shareholding

Insiders
5.53%
Institutions
110.39%

Largest institutional holders

FundStake
BlackRock Inc12.09%
Vanguard Group Inc5.74%
Vanguard Capital Management, LLC3.62%
Soleus Capital Management, L.P.3.61%
State Street Corp3.39%
TANG CAPITAL MANAGEMENT LLC3.11%
Goldentree Asset Management LP2.94%
Deep Track Capital, LP2.64%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ANI Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.